Proteins from Avastin® (bevacizumab) show tyrosine nitrations for which the consequences are completely unclear.
Avastin® (bevacizumab) is a protein drug widely used for cancer treatment although its further use is questionable due to serious side effects reported. As no systematic proteomic study on posttranslational modifications (PTMs) was reported so far, it was the aim of the current study to use a gel-ba...
Guardado en:
Autores principales: | Jia Wan, Edina Csaszar, Wei-Qiang Chen, Kongzhao Li, Gert Lubec |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2012
|
Materias: | |
Acceso en línea: | https://doaj.org/article/9856473a8af342a69c4c0b6cc2f6c8f6 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Pharmacokinetics of intravitreal bevacizumab (Avastin®) in rabbits
por: Sinapis C, et al.
Publicado: (2011) -
Bevacizumab (Avastin®) for the management of anterior chamber neovascularization and neovascular glaucoma
por: Dimitrios Brouzas, et al.
Publicado: (2009) -
Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to retinal vein occlusion
por: Juan Carlos Mesa Gutiérrez, et al.
Publicado: (2008) -
An unclear, chronic ulcer
por: Carolina Talhari, et al.
Publicado: (2011) -
VISUAL OUTCOME AFTER INTRAVITREAL BEVACIZUMAB (AVASTIN) IN THE TREATMENT OF BRANCH RETINAL VEIN OCCLUSION
por: Saquib Naeem, et al.
Publicado: (2019)